NeuroSense Therapeutics (NRSN)

• Market cap: $29.6M
• 1 day: 0.85%
• 5 days: -4.84%
• 1 month: -5.6%
• 3 months: -50.83%
• 6 months: 0%
• Year to date: 2.61%
• 1 year: -11.94%
• 5 years: -70.79%
• 10 years: -70.79%
• Sector: Healthcare
• Industry: Biotechnology

About: NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Employees: 15

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

371% more capital invested

Capital invested by funds: $181K [Q1] → $851K (+$670K) [Q2]

167% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 3

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

45% more funds holding

Funds holding: 11 [Q1] → 16 (+5) [Q2]

1.04% more ownership

Funds ownership: 0.84% [Q1] → 1.88% (+1.04%) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $14
• Avg. target: $14
• High target: $14

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

D. Boral Capital Jason Kolbert

$14

Buy Maintained

15 Aug 2025